(LIVN) LivaNova - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 3.489m USD | Total Return: 80.2% in 12m

Heart Machines, Oxygenators, Vagus Therapy, Epilepsy Devices, Sleep Apnea
Total Rating 55
Safety 30
Buy Signal 0.22
Medical Devices
Industry Rotation: -5.6
Market Cap: 3.49B
Avg Turnover: 47.5M USD
ATR: 3.51%
Peers RS (IBD): 85.6
Risk 5d forecast
Volatility36.3%
Rel. Tail Risk-16.8%
Reward TTM
Sharpe Ratio1.23
Alpha45.62
Character TTM
Beta0.969
Beta Downside2.256
Drawdowns 3y
Max DD47.23%
CAGR/Max DD0.30
EPS (Earnings per Share) EPS (Earnings per Share) of LIVN over the last years for every Quarter: "2021-03": 0.35, "2021-06": 0.52, "2021-09": 0.68, "2021-12": 0.57, "2022-03": 0.48, "2022-06": 0.53, "2022-09": 0.58, "2022-12": 0.81, "2023-03": 0.43, "2023-06": 0.78, "2023-09": 0.73, "2023-12": 0.87, "2024-03": 0.73, "2024-06": 0.93, "2024-09": 0.9, "2024-12": 0.81, "2025-03": 0.88, "2025-06": 1.05, "2025-09": 1.11, "2025-12": 0.86,
EPS CAGR: 16.82%
EPS Trend: 80.2%
Last SUE: 0.45
Qual. Beats: 0
Revenue Revenue of LIVN over the last years for every Quarter: 2021-03: 247.603, 2021-06: 264.483, 2021-09: 253.215, 2021-12: 270.064, 2022-03: 240.175, 2022-06: 254.151, 2022-09: 252.605, 2022-12: 274.874, 2023-03: 263.418, 2023-06: 293.882, 2023-09: 286.113, 2023-12: 310.132, 2024-03: 294.912, 2024-06: 318.575, 2024-09: 318.12, 2024-12: 321.83, 2025-03: 316.855, 2025-06: 352.524, 2025-09: 357.8, 2025-12: 360.855,
Rev. CAGR: 11.47%
Rev. Trend: 97.0%
Last SUE: 2.19
Qual. Beats: 14
Warnings

Interest Coverage Ratio -2.8 is critical

Altman Z'' -1.98 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: LIVN LivaNova

LivaNova PLC (NASDAQ:LIVN) is a UK-based medical-technology firm that develops and markets devices for both cardiopulmonary surgery and neuromodulation therapies. Its two business lines are the Cardiopulmonary segment-supplying heart-lung machines, oxygenators, autotransfusion and perfusion accessories-and the Neuromodulation segment, which offers the VNS Therapy System for refractory epilepsy, treatment-resistant depression, and other vagus-nerve-stimulation applications.

In the latest quarter (Q4 2025), LivaNova reported total revenue of $1.02 billion, a 7 % year-over-year increase, with the Neuromodulation segment contributing roughly 55 % of sales. The company invested $120 million in R&D (≈12 % of revenue) and ended the period with $300 million of cash and short-term investments, supporting its pipeline of next-generation neuro-stimulation devices.

Key macro drivers include rising global healthcare spending-projected to grow 4 % annually-and an aging population that fuels demand for both cardiac surgery equipment and chronic-disease neuromodulation solutions, trends that align with LivaNova’s product portfolio.

For a deeper quantitative analysis, consider reviewing the company’s profile on ValueRay.

Headlines to Watch Out For
  • Cardiopulmonary product sales drive revenue growth
  • VNS Therapy System adoption impacts neuromodulation segment
  • Regulatory approvals for new devices influence market access
  • Global healthcare spending trends affect product demand
Piotroski VR‑10 (Strict) 5.5
Net Income: -242.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.23 > 1.0
NWC/Revenue: 21.15% < 20% (prev 58.64%; Δ -37.50% < -1%)
CFO/TA 0.10 > 3% & CFO 254.3m > Net Income -242.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.36 > 1.5 & < 3
Outstanding Shares: last quarter (54.5m) vs 12m ago -0.37% < -2%
Gross Margin: 68.04% > 18% (prev 0.69%; Δ 6.73k% > 0.5%)
Asset Turnover: 54.30% > 50% (prev 50.01%; Δ 4.29% > 0%)
Interest Coverage Ratio: -2.79 > 6 (EBITDA TTM -120.6m / Interest Expense TTM 58.2m)
Altman Z'' -1.98
A: 0.11 (Total Current Assets 1.10b - Total Current Liabilities 808.1m) / Total Assets 2.61b
B: -0.44 (Retained Earnings -1.15b / Total Assets 2.61b)
C: -0.06 (EBIT TTM -162.6m / Avg Total Assets 2.56b)
D: -0.81 (Book Value of Equity -1.15b / Total Liabilities 1.41b)
Altman-Z'' Score: -1.98 = D
Beneish M -3.24
DSRI: 0.87 (Receivables 216.0m/223.7m, Revenue 1.39b/1.25b)
GMI: 1.02 (GM 68.04% / 69.16%)
AQI: 1.00 (AQ_t 0.46 / AQ_t-1 0.46)
SGI: 1.11 (Revenue 1.39b / 1.25b)
TATA: -0.19 (NI -242.5m - CFO 254.3m) / TA 2.61b)
Beneish M-Score: -3.24 (Cap -4..+1) = AA
What is the price of LIVN shares? As of April 06, 2026, the stock is trading at USD 63.79 with a total of 678,900 shares traded.
Over the past week, the price has changed by +4.11%, over one month by -1.41%, over three months by +0.89% and over the past year by +80.20%.
Is LIVN a buy, sell or hold? LivaNova has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy LIVN.
  • StrongBuy: 4
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LIVN price?
Analysts Target Price 79.9 25.3%
LivaNova (LIVN) - Fundamental Data Overview as of 05 April 2026
P/E Forward = 15.1515
P/S = 2.5134
P/B = 2.9082
P/EG = 0.7322
Revenue TTM = 1.39b USD
EBIT TTM = -162.6m USD
EBITDA TTM = -120.6m USD
Long Term Debt = 345.2m USD (from longTermDebt, last quarter)
Short Term Debt = 31.5m USD (from shortTermDebt, last quarter)
Debt = 473.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -162.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.33b USD (3.49b + Debt 473.3m - CCE 635.6m)
Interest Coverage Ratio = -2.79 (Ebit TTM -162.6m / Interest Expense TTM 58.2m)
EV/FCF = 19.19x (Enterprise Value 3.33b / FCF TTM 173.3m)
FCF Yield = 5.21% (FCF TTM 173.3m / Enterprise Value 3.33b)
FCF Margin = 12.49% (FCF TTM 173.3m / Revenue TTM 1.39b)
Net Margin = -17.47% (Net Income TTM -242.5m / Revenue TTM 1.39b)
Gross Margin = 68.04% ((Revenue TTM 1.39b - Cost of Revenue TTM 443.6m) / Revenue TTM)
Gross Margin QoQ = 66.45% (prev 68.45%)
Tobins Q-Ratio = 1.28 (Enterprise Value 3.33b / Total Assets 2.61b)
Interest Expense / Debt = 4.18% (Interest Expense 19.8m / Debt 473.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -128.4m (EBIT -162.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.36 (Total Current Assets 1.10b / Total Current Liabilities 808.1m)
Debt / Equity = 0.39 (Debt 473.3m / totalStockholderEquity, last quarter 1.20b)
 Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -162.3m / EBITDA -120.6m)
 Debt / FCF = -0.94 (Net Debt -162.3m / FCF TTM 173.3m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.49% (Net Income -242.5m / Total Assets 2.61b)
RoE = -21.49% (Net Income TTM -242.5m / Total Stockholder Equity 1.13b)
RoCE = -11.03% (EBIT -162.6m / Capital Employed (Equity 1.13b + L.T.Debt 345.2m))
 RoIC = -8.05% (negative operating profit) (NOPAT -128.4m / Invested Capital 1.60b)
 WACC = 8.66% (E(3.49b)/V(3.96b) * Re(9.39%) + D(473.3m)/V(3.96b) * Rd(4.18%) * (1-Tc(0.21)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.92%
[DCF] Terminal Value 79.46% ; FCFF base≈158.4m ; Y1≈195.4m ; Y5≈333.3m
[DCF] Fair Price = 95.06 (EV 5.04b - Net Debt -162.3m = Equity 5.20b / Shares 54.7m; r=8.66% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 80.20 | EPS CAGR: 16.82% | SUE: 0.45 | # QB: 0
Revenue Correlation: 96.98 | Revenue CAGR: 11.47% | SUE: 2.19 | # QB: 14
EPS next Quarter (2026-06-30): EPS=1.09 | Chg7d=+0.000 | Chg30d=-0.017 | Revisions Net=-3 | Analysts=10
EPS current Year (2026-12-31): EPS=4.21 | Chg7d=+0.000 | Chg30d=+0.077 | Revisions Net=+7 | Growth EPS=+7.9% | Growth Revenue=+7.3%
EPS next Year (2027-12-31): EPS=4.58 | Chg7d=+0.092 | Chg30d=+0.092 | Revisions Net=+9 | Growth EPS=+8.7% | Growth Revenue=+6.7%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle